|
Along with the layoffs, the reshuffle includes prioritisation of pipeline assets with the “highest probability of success.”
|
 |
|
Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for market share.
|
|
|
The approval aligns with recent regulatory decisions in countries including China and the US.
|
|
|
The OmniTAC platform enables unbiased screening of effector proteins that can modulate disease-relevant targets.
|
|
|
Aliada will receive upfront, sales-based payments, while Chiesi funds all development and commercialisation activities.
|
|
|
The research expands upon the investigator-initiated Phase II Nobel clinical study led by Dr Manabu Muto of Kyoto University.
|
|
